Your browser doesn't support javascript.
loading
Preparation and Evaluation of ZD2 Peptide 64Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer.
Han, Zheng; Sergeeva, Olga; Roelle, Sarah; Cheng, Han; Gao, Songqi; Li, Yajuan; Lee, Zhenghong; Lu, Zheng-Rong.
Afiliação
  • Han Z; Department of Biomedical Engineering and Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, United States.
  • Sergeeva O; Department of Biomedical Engineering and Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, United States.
  • Roelle S; Department of Biomedical Engineering and Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, United States.
  • Cheng H; Department of Biomedical Engineering and Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, United States.
  • Gao S; Department of Biomedical Engineering and Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, United States.
  • Li Y; Molecular Theranostics, Cleveland, Ohio 44115, United States.
  • Lee Z; Department of Biomedical Engineering and Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, United States.
  • Lu ZR; Department of Biomedical Engineering and Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106, United States.
ACS Omega ; 4(1): 1185-1190, 2019 Jan 31.
Article em En | MEDLINE | ID: mdl-30729224
ABSTRACT
Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The probe consists of a small ZD2 peptide specific to EDB-FN and a 64Cu-DOTA chelate. The probe was synthesized using standard solid-phase peptide chemistry and chelated to 64Cu prior to imaging. PET images were acquired at 4 and 22 h after intravenously injecting a 200 µCi probe into mice bearing human PC3 and LNCaP tumors, which represent highly aggressive and slow-growing prostate tumors, respectively. At 4 and 22 h postinjection, tumors could be clearly identified in the PET images. A significant higher signal was observed in PC3 tumors than in LNCaP tumors at 22 h (p = 0.01). Probe accumulation was also higher in PC3 tumors at 24 h. These data demonstrated that PET molecular imaging of EDB-FN in the tumor microenvironment of prostate cancer allows efficient differentiation of PC3 and LNCaP tumors in vivo. The ZD2 peptide-targeted PET probe shows potential in the detection and characterization of high-risk prostate cancer to improve the clinical management of prostate cancer.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article